Insider Transactions in Q2 2025 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$62,000
$31.98 P/Share
|
|
May 20
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
May 16
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.2%
|
$150,000
$30.93 P/Share
|
|
May 15
2025
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
1,454
-5.82%
|
$42,166
$29.73 P/Share
|
|
May 14
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+24.73%
|
-
|
|
May 14
2025
|
B Lynne Parshall Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+20.79%
|
-
|
|
May 14
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+9.05%
|
-
|
|
May 14
2025
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+22.7%
|
-
|
|
May 14
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+18.05%
|
-
|
|
May 14
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+18.56%
|
-
|
|
May 14
2025
|
Robert E Landry Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+50.0%
|
-
|
|
May 14
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+19.33%
|
-
|
|
May 06
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$70,000
$35.01 P/Share
|
|
May 06
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
May 05
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,002
-6.19%
|
$144,072
$36.68 P/Share
|
|
Apr 29
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.18%
|
$200,000
$40.96 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$76,000
$38.11 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
20,000
-44.6%
|
$760,000
$38.46 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.84%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
3,190
-4.59%
|
$121,220
$38.66 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.34%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+1.23%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+2.12%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
551
+0.82%
|
$20,938
$38.56 P/Share
|
|
Apr 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.69%
|
$6,156
$38.56 P/Share
|
|
Apr 15
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.65%
|
$6,156
$38.56 P/Share
|
|
Apr 10
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.17%
|
$180,000
$36.77 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$72,000
$36.18 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 07
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,886
-4.27%
|
$101,010
$35.78 P/Share
|
|
Apr 03
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
450
-2.98%
|
$17,550
$39.43 P/Share
|